Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 30;115(7):E1511–E1519. doi: 10.1073/pnas.1716452115

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published under the PNAS license.

PMC Copyright notice

Fig. 1. — Deletion of Cic from adult mice causes T cell acute lymphoblastic leukemia/lymphoma (T-ALL). (A) Tumor-free survival for UBC-cre/ERT2; Cic^flox/flox mice treated with tamoxifen (TAM) or vehicle (Veh), or control genotypes treated with tamoxifen. The median survival age was 37.6 wk for the UBC-cre/ERT2; Cic^flox/flox mice treated with tamoxifen. (B) Representative image of the T cell lymphomas observed in the Cic adult knockout mice. (Scale bar: 0.5 cm.) (C) Flow cytometry analyses of the thymus and bone marrow from the Cic adult knockout mice at their respective humane endpoint and analysis of an age-matched Cic^flox/flox control mice. Representative results are shown for a mouse with T cell lymphoblastic lymphoma and a mouse with T cell lymphoblastic leukemia. (D) Histology of a control Cic^flox/flox mouse and a UBC-cre/ERT2; Cic^flox/flox mouse with T cell lymphoblastic lymphoma and one with T cell lymphoblastic leukemia. Note the blast morphology of T cells in the lymphomas from the UBC-cre/ERT2; Cic^flox/flox mice. (Scale bars: 100 μm.) (E) Latency and immunophenotypes of tumors from the UBC-cre/ERT2; Cic^flox/flox mice. DP, CD4⁺ CD8⁺ double positive.